Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity
Open Access
- 1 October 2000
- journal article
- cell based-therapy
- Published by Springer Nature in Gene Therapy
- Vol. 7 (19) , 1680-1689
- https://doi.org/10.1038/sj.gt.3301288
Abstract
The identification of dendritic cells (DC) as the major antigen-presenting cell type of the immune system, combined with the development of procedures for their ex vivo culture, has opened possibilities for tumour immunotherapy based on the transfer of recombinant tumour antigens to DC. It is anticipated that the most effective type of response would be the stimulation of specific, MHC class I restricted cytotoxic T lymphocytes capable of recognising and destroying tumour cells. In order to make this approach possible, methods must be developed for the transfer of recombinant antigen to the DC in such a way that they will initiate an MHC class I restricted response. Here, we demonstrate that murine DC infected with a recombinant fowlpox virus (rFWPV) vector stimulate a powerful, MHC class I restricted response against a recombinant antigen. A rFWPV containing the OVA gene was constructed and used to infect the DC line DC2.4. The infected DC2.4 cells were found to stimulate the T-T cell hybridoma line RF33.70, which responds specifically to the MHC class I restricted OVA peptide SIINFEKL. The stimulatory ability of the rFWPV-infected DC2.4 cells lasted for at least 72 h after infection and was eventually limited by proliferation of uninfected cells. By comparison, DC2.4 cells pulsed with synthetic SIINFEKL peptide stimulated RF33.70 well initially, but the stimulatory ability had declined to zero by 24 h after pulsing. FWPV infection of DC2.4 up-regulated MHC and costimulatory molecule expression. rFWPV was also found to infect both immature and mature human DC derived from cord blood CD34+ progenitors and express trangenes for up to 20 days after infection. We conclude that rFWPV shows promise as a vector for antigen gene transfer to DC in tumour immunotherapy protocols.Keywords
This publication has 37 references indexed in Scilit:
- Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectorsCancer Gene Therapy, 1999
- CD34+AC133+Cells Isolated from Cord Blood are Highly Enriched in Long‐Term Culture‐Initiating Cells, NOD/SCID‐Repopulating Cells and Dendritic Cell ProgenitorsThe International Journal of Cell Cloning, 1998
- Duration of TCR Stimulation Determines Costimulatory Requirement of T CellsImmunity, 1996
- Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.The Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunology Today, 1995
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992
- Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSFEuropean Journal of Cancer and Clinical Oncology, 1990
- Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) DiseaseNew England Journal of Medicine, 1987
- Vaccinia Virus Polypeptide Synthesis: sequential Appearance and Stability of Pre- and Post-replicative PolypeptidesJournal of General Virology, 1974